Share with your CIO
Cent, the Bengaluru-based preventive healthcare startup founded by Practo’s Shashank ND, is betting that combining full-body MRI, CT, DEXA, ECG, and over 100 biomarkers into a single two-hour session is a repeatable business, not just a concierge curiosity. The company closed a $15 million Series A co-led by Blume Ventures and South Park Commons, and acquired AI radiology platform Medsee to automate the interpretation of growing scan volumes. Ten thousand people have screened so far; one in four had actionable findings.
What this means for your business
The Medsee acquisition is the tell. Cent’s protocol generates enormous imaging throughput, and human radiologists are the bottleneck that breaks the unit economics before you reach scale. An AI layer that accelerates radiology reporting isn’t a feature; it’s the condition under which 10 million scans by 2035 becomes arithmetically possible rather than aspirational. CIOs evaluating health-tech vendors or building employee wellness infrastructure should watch whether Cent’s integrated-stack approach (owned hardware, proprietary AI, captive centers) holds together at volume, because the failure mode for this model is quality drift when scan counts multiply faster than clinical oversight can follow.
India’s chronic disease burden, 101 million diabetics, 315 million people with hypertension, gives Cent a demand environment that justifies the ambition. But the more interesting signal for enterprise buyers is the architecture decision underneath it: Cent controls the full diagnostic pipeline rather than reselling third-party lab networks. That’s a deliberate margin and quality bet. Companies that have tried the asset-light diagnostics model in India repeatedly discovered that partner lab variability destroys standardization, which is precisely what an AI model trained on your own consistent imaging data cannot tolerate. Vertical integration here isn’t stubbornness; it’s a prerequisite for the training data to stay clean.
The falsification condition worth tracking is this: if Cent’s reported finding rate, one in four screenees with actionable results, holds up under independent clinical audit as it scales beyond 10,000 patients, the model is credible. If that rate compresses toward what routine check-ups already catch, the AI differentiation was mostly a premium-pricing story. Enterprises considering Cent as a workforce health benefit, or health-tech leaders benchmarking their own diagnostic AI strategy against it, should demand that audit before the next funding round makes the question impolite to ask.
Based on reporting from Cent Raises $15 Million in Series A Funding, Acquires AI Startup Medsee, originally published 2026-10-27 09:29:00.
